Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000400 · ClinicalTrials.gov registry record · Phase 2
Alendronate and/or Parathyroid Hormone for Osteoporosis
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT00000400: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00000400 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 176 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000400, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
Interventions
- DRUG alendronate
- DRUG Human parathyroid hormone [hPTH-(1-34)]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 1999-08 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000400
The ClinicalTrials.gov registry entry for NCT00000400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which alendronate is the first listed.
NCT00000400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000400 about?
NCT00000400 is a clinical study titled "Alendronate and/or Parathyroid Hormone for Osteoporosis". This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH...
What is the current status of trial NCT00000400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 1999-08. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00000400?
The interventions under investigation include: alendronate (DRUG), Human parathyroid hormone [hPTH-(1-34)] (DRUG).
Who is sponsoring clinical trial NCT00000400?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.